- Baricitinib, sold
under the
brand name
Olumiant among others, is an
immunomodulatory medication used for the
treatment of
rheumatoid arthritis, alopecia...
-
Evaluation and (2019-02-09). "Drug
Trials Snapshots:
OLUMIANT". FDA. "Drug
Approval Package:
Olumiant (baricitinib)". www.accessdata.fda.gov.
Retrieved 2021-07-27...
- coated". DailyMed. 28 July 2021.
Retrieved 25 June 2023. "FDA
Approves Olumiant (baricitinib) 2-mg
Tablets for the
Treatment of
Adults with Moderately-to-Severely...
- On June 13, 2022, the U.S. Food and Drug
Administration (FDA)
approved Olumiant (baricitinib) for
adults with
severe alopecia areatal. It is the first...
- 1159/000441250. PMID 26735937. S2CID 207742214. "FDA
Approves Lilly and Incyte's
Olumiant (baricitinib) As
First and Only
Systemic Medicine for
Adults with Severe...
-
include Trulicity, Mounjaro, Verzenio, Taltz, Jardiance, Humalog, Cyramza,
Olumiant, Emgality, Tyvyt, Retevmo, Alimta, and Zepbound. In 2003, Eli
Lilly and...
-
Litfulo enters the
scene in
alopecia with
adolescent nod to
rival Lilly's
Olumiant".
Fierce Pharma.
Archived from the
original on 8 July 2023.
Retrieved 18...
- (Dupixent),
tralokinumab (Adtralza, Adbry),
abrocitinib (Cibinqo),
baricitinib (
Olumiant) and
upadacitinib (Rinvoq).
Among monoclonal antibodies,
dupilumab and...
- source,
which is in the
public domain. "FDA
Approves Lilly and Incyte's
Olumiant (baricitinib) As
First and Only
Systemic Medicine for
Adults with Severe...
- source,
which is in the
public domain. "Frequently
Asked Questions on
Olumiant (Baricitinib) for the
Treatment of COVID-19" (PDF). U.S. Food and Drug...
